A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN’S PATIENTS REFRACTORY TO ANTI-TNF THERAPY

Patients with moderate to severe Crohn’s disease refractory or intolerant to steroids, immunomodulators and anti-TNF therapy currently have few options for medical management outside of clinical trials. Ustekinumab, a monoclonal antibody, which inhibits interleukins 12 and 23 is currently being used safely and effectively to treat patients with psoriasis and recent studies suggest that it may be of value in treating moderate to severe Crohn’s disease in patients both naive and refractory to anti-TNF therapy. Currently the intravenous formulation of ustekinumab used in these studies is unavailable for use outside of clinical trials. The aim of this study was to examine the clinical efficacy of subcutaneously (sc) loaded ustekinumab in patients with moderate to severe Crohn’s disease who had failed at least one anti-TNF agent. All patients given a loading dose of ustekinumab 270 mg sc over two weeks were included in this retrospective analysis. Baseline demographic data was collected. The primary outcome was the proportion of patients who achieved a Harvey-Bradshaw Index (HBI)